2000
A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma
Small E, Figlin R, Petrylak D, Vaughn D, Sartor O, Horak I, Pincus R, Kremer A, Bowden C. A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma. Investigational New Drugs 2000, 18: 193-198. PMID: 10857997, DOI: 10.1023/a:1006386115312.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotics, AntineoplasticCarcinoma, Renal CellDuocarmycinsFemaleHumansKidney NeoplasmsMaleMiddle AgedPilot ProjectsPyrrolidinonesConceptsRenal cell carcinomaMetastatic renal cell carcinomaCell carcinomaOpen-label phase II trialCommon drug-related toxicitiesAdvanced renal cell carcinomaPhase II pilot studyNon-hematologic toxicitiesPhase II trialDrug-related toxicityPredictable safety profileReversible myelosuppressionII trialObjective responseSafety profileDisease progressionModerate fatigueWeek 6PatientsSignificant toxicityCarcinomaPilot studyAntitumor potencyWater-soluble analogueCycle 1
1995
Chemotherapy for advanced renal-cell carcinoma: 1983-1993.
Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Seminars In Oncology 1995, 22: 42-60. PMID: 7855619.Peer-Reviewed Original Research
1993
CYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA
Yagoda A, Petrylak D, Thompson S. CYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA. Urologic Clinics Of North America 1993, 20: 303-321. PMID: 8493752, DOI: 10.1016/s0094-0143(21)00489-4.Peer-Reviewed Original Research
1989
Interleukin‐2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers
Baker H, Marcus S, Frank O, Petrylak D, Deangelis B, Dutcher J, Wiernik P. Interleukin‐2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers. Cancer 1989, 64: 1226-1231. PMID: 2788491, DOI: 10.1002/1097-0142(19890915)64:6<1226::aid-cncr2820640611>3.0.co;2-m.Peer-Reviewed Original ResearchConceptsIL-2 treatmentAdoptive immunotherapyInterleukin-2Biopterin productionPlasma biopterinMetastatic renal cell carcinomaIL-2 activationIL-2 exposureAdoptive immunotherapy protocolsMetastatic colon cancerRenal cell carcinomaLAK treatmentImmunotherapy protocolsKiller cellsLAK cellsImmunotherapy treatmentCell carcinomaPlasma catecholaminesTumor regressionCatecholamine productionMalignant melanomaLeukocyte populationsTotal biopterinLeukocyte activationImmunotherapy